Publicité
Publicité
CBIO
Crescent Biopharma, Inc. Common Stock
10.81
USDSponsorisé
-0.16
-1.41%
09 janv., 15:59 UTC -5
Fermé
Après-marché
10.80
-0.01
-0.09%
CBIO Rapports sur les bénéfices
Ratio de surprise positive
CBIO a dépassé 29 des 38 dernières estimations.
76%
Prochain rapport
Date du prochain rapport
09 févr. 2026
Estimate for Q4 25 (Revenue/ EPS)
$5.10M
/-$2.51
Variation implicite de Q3 25 (Revenue/ EPS)
--
/+97.64%
Variation implicite de Q4 24 (Revenue/ EPS)
--
/--
Crescent Biopharma, Inc. Common Stock earnings per share and revenue
On 06 nov. 2025, CBIO reported earnings of -1.27 USD per share (EPS) for Q3 25, beating the estimate of -2.02 USD, resulting in a 37.18% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +5.39% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analystes forecast an EPS of -2.51 USD, with revenue projected to reach 5.10 million USD, implying an hausse of 97.64% EPS, and -- of --% in Revenue from the last quarter.
FAQ
What were Crescent Biopharma, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Crescent Biopharma, Inc. Common Stock reported EPS of -$1.27, beating estimates by 37.18%, and revenue of $0.00, 0% as expectations.
How did the market react to Crescent Biopharma, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 5.39%, changed from $12.43 before the earnings release to $13.10 the day after.
When is Crescent Biopharma, Inc. Common Stock expected to report next?
The next earning report is scheduled for 09 févr. 2026.
What are the forecasts for Crescent Biopharma, Inc. Common Stock's next earnings report?
Based on 8
analystes, Crescent Biopharma, Inc. Common Stock is expected to report EPS of -$2.51 and revenue of $5.10M for Q4 2025.
Which companies are reporting earnings today?
Chèque FXEmpire's Earnings Calendar for today's list of reporting companies.
Publicité